RNA Formulation Videos
-
Durable Liquid Nanoparticle (LNP) Systems
12/6/2024
Discover the benefits of an LNP system that offers unparalleled durability and sustainability. Eliminate wear parts, plastic waste, and running costs with a system designed for long-term performance and minimal environmental impact.
-
Face- Phase-Off: Matching CDMO Capabilities To Your mRNA-LNP Development Stage
2/10/2025
There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.
-
Q&A On Formulation & Stability Of LNPs
11/28/2022
Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, address audience questions around the importance of drug substance and drug product stability in efficient delivery in this segment of the Bioprocess Online Live! event LNPs & Beyond: Opportunities in RNA Delivery.
-
Insights And Strategies For GMP Manufacturing Of RNA-Lipid Nanoparticles
4/25/2024
The emergence of RNA-encapsulated-lipid nanoparticles has introduced a seismic shift in biopharma innovation. But how will the industry adapt to diversifying applications and scales going forward?
-
What Does 2025 (And Beyond) Hold For The RNA-LNP Space?
12/4/2024
Three LNP experts share their thoughts on the incremental advancements they’d like to see the RNA-LNP space make in the next few years.
-
Keys To Successful mRNA Manufacturing
4/26/2022
How can PCR-based technology accelerate mRNA development and manufacturing and design principles/critical parameters to enable the rapid development of lipids for RNA formulation?
-
Polysarcosine-Functionalized LNPs For Therapeutic mRNA Delivery
4/14/2022
Discover how polysarcosine-functionalized lipid nanoparticles are transforming mRNA delivery. Join Dr. Heinrich Haas of BioNTech as he unveils innovative research and its implications for therapeutic breakthroughs.
-
The NanoAssemblr® Spark™ Robust Low Volume RNA-Lipid Nanoparticle Formulation
4/14/2022
Develop RNA-lipid nanoparticles (LNPs) in under 10 seconds for drug discovery and early preclinical development. The NanoAssemblr®️ Spark™ instrument enables rapid µL formulations to conserve limited and expensive ingredients with minimal waste.
-
A Benchtop System For Lipid Nanoparticle (LNP) Formulation
12/6/2024
Discover the unparalleled flexibility and automation that sets the IJM NanoScaler Pro apart from other lipid nanoparticle systems.
-
Defining A "Next-Gen" LNP
11/28/2022
Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.